| Title |
New treatment options with cytotoxic agents in neuroendocrine tumours
|
|---|---|
| Published in |
Targeted Oncology, August 2012
|
| DOI | 10.1007/s11523-012-0228-7 |
| Pubmed ID | |
| Authors |
Pascal Hammel, Olivia Hentic, Cindy Neuzillet, Sandrine Faivre, Eric Raymond, Philippe Ruszniewski |
| Abstract |
There are numerous treatment options for patients with advanced digestive neuroendocrine tumours (NETs). Medical treatment includes systemic chemotherapies, targeted therapies, somatostatin analogs, liver-directed therapies such as (chemo)embolization or thermoablation, and peptide receptor radionuclide therapy. Cytotoxic chemotherapies can help control tumour progression in patients with non-resectable tumours and may improve symptoms by reducing tumour bulk. In addition, tumour response is usually greater than that obtained with targeted therapies. This should be taken into consideration in neoadjuvant strategies. Efficacy of temozolomide depends on the O(6) methylguanine DNA methyl transferase status, and thus, this drug will likely have to be considered in the future in patients with a favourable enzyme profile. Because numerous treatment options are available for patients with advanced digestive NETs, and thanks to their long survival, successive drugs should be used. Careful attention should be paid to the adverse events in order to maintain the quality of life in these patients who have with a long life expectancy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 8% |
| Unknown | 11 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 33% |
| Other | 2 | 17% |
| Student > Doctoral Student | 1 | 8% |
| Professor | 1 | 8% |
| Student > Bachelor | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 3 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 58% |
| Psychology | 1 | 8% |
| Nursing and Health Professions | 1 | 8% |
| Unknown | 3 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2013.
All research outputs
#18,354,532
of 22,731,677 outputs
Outputs from Targeted Oncology
#389
of 548 outputs
Outputs of similar age
#129,677
of 169,250 outputs
Outputs of similar age from Targeted Oncology
#3
of 5 outputs
Altmetric has tracked 22,731,677 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 548 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,250 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.